3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
4
Active not recruiting
3
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Conditions
Carcinoma, Non-Small-Cell Lung
29
Breast Neoplasms
17
Neoplasms
14
Neoplasm Metastasis
10
Ovarian Neoplasms
9
Carcinoma, Renal Cell
8
Melanoma
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Colorectal Neoplasms
7
Urinary Bladder Neoplasms
6
Small Cell Lung Carcinoma
6
Recurrence
6
Multiple Myeloma
6
Lymphoma, Non-Hodgkin
6
Thyroid Neoplasms
5
Thyroid Cancer, Papillary
5
Prostatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Pancreatic Neoplasms
5
Lung Neoplasms
5
Hematologic Neoplasms
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Colonic Neoplasms
5
Lymphoma
4
Leukemia, Myeloid, Acute
4
Urothelial Cancer
3
Stomach Neoplasms
3
Sarcoma
3
Salivary Gland Neoplasms
3
Interventions
durvalumab
2
Pemetrexed
2
Cisplatin
2
Carboplatin
2
tremelimumab
1
osimertinib
1
Surgical Procedures, Operative
1
Paclitaxel
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Has announcements
×
Carcinoma
×
Clear all
NCT03703297
2025-11-21
ADRIATIC
AstraZeneca
Phase 3
Active not recruiting
730 enrolled
19 charts
1 FDA
NCT04035486
2025-10-10
FLAURA2
AstraZeneca
Phase 3
Active not recruiting
587 enrolled
44 charts
1 FDA
NCT03800134
2025-06-11
AEGEAN
AstraZeneca
Phase 3
Active not recruiting
825 enrolled
1 FDA